Literature DB >> 28124579

Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial.

Laura Balzer1, Patrick Staples1, Jukka-Pekka Onnela1, Victor DeGruttola1.   

Abstract

BACKGROUND: Several cluster-randomized trials are underway to investigate the implementation and effectiveness of a universal test-and-treat strategy on the HIV epidemic in sub-Saharan Africa. We consider nesting studies of pre-exposure prophylaxis within these trials. Pre-exposure prophylaxis is a general strategy where high-risk HIV- persons take antiretrovirals daily to reduce their risk of infection from exposure to HIV. We address how to target pre-exposure prophylaxis to high-risk groups and how to maximize power to detect the individual and combined effects of universal test-and-treat and pre-exposure prophylaxis strategies.
METHODS: We simulated 1000 trials, each consisting of 32 villages with 200 individuals per village. At baseline, we randomized the universal test-and-treat strategy. Then, after 3 years of follow-up, we considered four strategies for targeting pre-exposure prophylaxis: (1) all HIV- individuals who self-identify as high risk, (2) all HIV- individuals who are identified by their HIV+ partner (serodiscordant couples), (3) highly connected HIV- individuals, and (4) the HIV- contacts of a newly diagnosed HIV+ individual (a ring-based strategy). We explored two possible trial designs, and all villages were followed for a total of 7 years. For each village in a trial, we used a stochastic block model to generate bipartite (male-female) networks and simulated an agent-based epidemic process on these networks. We estimated the individual and combined intervention effects with a novel targeted maximum likelihood estimator, which used cross-validation to data-adaptively select from a pre-specified library the candidate estimator that maximized the efficiency of the analysis.
RESULTS: The universal test-and-treat strategy reduced the 3-year cumulative HIV incidence by 4.0% on average. The impact of each pre-exposure prophylaxis strategy on the 4-year cumulative HIV incidence varied by the coverage of the universal test-and-treat strategy with lower coverage resulting in a larger impact of pre-exposure prophylaxis. Offering pre-exposure prophylaxis to serodiscordant couples resulted in the largest reductions in HIV incidence (2% reduction), and the ring-based strategy had little impact (0% reduction). The joint effect was larger than either individual effect with reductions in the 7-year incidence ranging from 4.5% to 8.8%. Targeted maximum likelihood estimation, data-adaptively adjusting for baseline covariates, substantially improved power over the unadjusted analysis, while maintaining nominal confidence interval coverage.
CONCLUSION: Our simulation study suggests that nesting a pre-exposure prophylaxis study within an ongoing trial can lead to combined intervention effects greater than those of universal test-and-treat alone and can provide information about the efficacy of pre-exposure prophylaxis in the presence of high coverage of treatment for HIV+ persons.

Entities:  

Keywords:  Adaptive pre-specification; HIV; cluster-randomized trials; networks; pre-exposure prophylaxis; targeted maximum likelihood estimation

Mesh:

Substances:

Year:  2017        PMID: 28124579      PMCID: PMC5377920          DOI: 10.1177/1740774516679666

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  31 in total

1.  Simple, efficient estimators of treatment effects in randomized trials using generalized linear models to leverage baseline variables.

Authors:  Michael Rosenblum; Mark J van der Laan
Journal:  Int J Biostat       Date:  2010-04-01       Impact factor: 0.968

2.  Adaptive pre-specification in randomized trials with and without pair-matching.

Authors:  Laura B Balzer; Mark J van der Laan; Maya L Petersen
Journal:  Stat Med       Date:  2016-07-19       Impact factor: 2.373

3.  An experimental design for the development of adaptive treatment strategies.

Authors:  S A Murphy
Journal:  Stat Med       Date:  2005-05-30       Impact factor: 2.373

4.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

6.  Factorial experiments: efficient tools for evaluation of intervention components.

Authors:  Linda M Collins; John J Dziak; Kari C Kugler; Jessica B Trail
Journal:  Am J Prev Med       Date:  2014-08-01       Impact factor: 5.043

7.  Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach.

Authors:  Anastasios A Tsiatis; Marie Davidian; Min Zhang; Xiaomin Lu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

8.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

9.  Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.

Authors:  Alethea W McCormick; Nadia N Abuelezam; Erin R Rhode; Taige Hou; Rochelle P Walensky; Pamela P Pei; Jessica E Becker; Madeline A DiLorenzo; Elena Losina; Kenneth A Freedberg; Marc Lipsitch; George R Seage
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

10.  A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study.

Authors:  Gabriel Chamie; Tamara D Clark; Jane Kabami; Kevin Kadede; Emmanuel Ssemmondo; Rachel Steinfeld; Geoff Lavoy; Dalsone Kwarisiima; Norton Sang; Vivek Jain; Harsha Thirumurthy; Teri Liegler; Laura B Balzer; Maya L Petersen; Craig R Cohen; Elizabeth A Bukusi; Moses R Kamya; Diane V Havlir; Edwin D Charlebois
Journal:  Lancet HIV       Date:  2016-01-26       Impact factor: 12.767

View more
  2 in total

Review 1.  The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward.

Authors:  Kelsey K Case; Gabriela B Gomez; Timothy B Hallett
Journal:  J Int AIDS Soc       Date:  2019-09       Impact factor: 5.396

2.  Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020.

Authors:  Linda-Gail Bekker; Benjamin Brown; Dvora Joseph-Davey; Kathrine Gill; Michelle Moorhouse; Sinead Delany-Moretlwe; Landon Myer; Catherine Orrell; Kevin Rebe; W D Francois Venter; Carole L Wallis
Journal:  South Afr J HIV Med       Date:  2020-12-10       Impact factor: 2.744

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.